Medical News

RSS

Worst effects of reperfusion injury after heart attack may be prevented with iodide

Blocked arteries are typically the trigger, stopping the flow of blood and starving the heart muscle of oxygen. But when the blockage is removed and the blood comes rushing back, it wreaks havoc of its own. The result is called reperfusion injury, a life-threatening flood of inflammation and cellular destruction that has stumped scientists for 40 years.

9 Nov 2014

Prof. Dan Peer awarded grant for groundbreaking development in cancer treatment

Prof. Dan Peer of Tel Aviv University's Department of Cell Research and Immunology will be awarded $10,000 for his groundbreaking development in cancer treatment at the inaugural Untold News Awards on Wednesday, November 12, 2014, from 6:00 to 8:00 p.m. at the Harmonie Club in New York City.

9 Nov 2014

Researchers find way to defeat elusive target proteins in cancer cells

Researchers at Dana-Farber/Boston Children's Cancer and Blood Disorders Center have found a way to defeat one of the most tantalizing yet elusive target proteins in cancer cells - employing a strategy that turns the protein's own molecular machinations against it.

9 Nov 2014

New vaccination approach can reduce tumor burden, suppress formation of lung metastases

In a new study published in the scientific journal Oncotarget researchers from Uppsala University show that a therapeutic vaccine directed against tumor vessels can reduce tumor burden and suppress formation of spontaneous lung metastases in a mouse model for metastatic breast cancer.

9 Nov 2014

Scientists may have discovered new way to repair damaged tissue

By transforming human scar cells into blood vessel cells, scientists at Houston Methodist may have discovered a new way to repair damaged tissue. The method, described in an upcoming issue of Circulation (early online), appeared to improve blood flow, oxygenation, and nutrition to areas in need.

9 Nov 2014

Johnson & Johnson completes acquisition of Alios BioPharma

Johnson & Johnson today announced the completion of the acquisition of Alios BioPharma, Inc., a privately held clinical stage biopharmaceutical company focused on developing therapies for viral diseases, for a total purchase price of approximately $1.75 billion in cash.

8 Nov 2014

SQI Diagnostics gets FDA clearance to market Celiac Panel in the US

SQI Diagnostics Inc. today announced that it has received notice that the United States Food and Drug Administration has cleared the Company to market its proprietary Celiac Panel in the United States (US).

8 Nov 2014

Actimab-A extends overall survival, reduces bone marrow blasts in older AML patients

Interim data from an ongoing Phase I/II trial of Actimab-A, an innovative targeted payload immunotherapy, demonstrated a number of positive findings, including extension of overall survival and significant reductions in bone marrow blasts in older patients with newly diagnosed Acute Myeloid Leukemia (AML).

7 Nov 2014

Stradis Healthcare signs definitive agreement to acquire Medikmark

Stradis Healthcare is pleased to announce that it has entered into a definitive acquisition agreement with Medikmark, a leading provider of healthcare kits based in Waukegan, IL, under which Stradis will acquire all shares of Medikmark.

7 Nov 2014

Blue Cross and Blue Shield of Texas launches Blue Directions for Small Business

Blue Cross and Blue Shield of Texas today announced the launch of Blue Directions for Small Business, a private exchange solution for companies with 1 – 50 employees. Blue Directions for Small Business helps employers elect health and dental benefit plans and customize contribution strategies on a convenient, user-friendly platform which also allows employees to choose group plans or individual marketplace plans.

7 Nov 2014

AlloSource recognized with CBSA's Company of the Year award

AlloSource, one of the nation's largest providers of skin, bone and soft tissue allografts for use in surgical procedures, and the world's largest processor of cellular bone allografts, has been named the Company of the Year by the Colorado BioScience Association. AlloSource is a repeat winner, having won this award in 2007.

7 Nov 2014

UCSD researchers describe surprising role of protein in embryonic development

Hematopoietic stem cells (HSCs) give rise to all blood and immune cells throughout the life of vertebrate organisms, from zebrafish to humans. But details of their genesis remain elusive, hindering efforts to develop induced pluripotent stem cell (iPSC) replacements that might address a host of blood disorders.

7 Nov 2014

Induced neural stem cells hold promise for therapeutic transplantation

Induced neural stem cells (iNSCs) created from adult cells hold promise for therapeutic transplantation, but their potential in this capacity has been limited by failed efforts to maintain such cells in the desirable multi-potent NSC state without continuous expression of the transcription factors used initially to reprogram them.

7 Nov 2014

Findings pave way for personalized probiotic therapies for obesity-related diseases

Our genetic makeup influences whether we are fat or thin by shaping which types of microbes thrive in our body, according to a Cornell-led study published today in the journal Cell.

7 Nov 2014

Researchers discover new genetic cause of rare, complex form of epilepsy

A research team led by scientists at the Scripps Translational Science Institute has used whole genome sequencing to identify a new genetic cause of a severe, rare and complex form of epilepsy that becomes evident in early childhood and can lead to early death.

7 Nov 2014

Eribulin drug has minor added benefit in one patient group, indication of lesser benefit in others

Eribulin (trade name: Halaven) is approved for women with locally advanced or metastatic breast cancer in whom the disease has progressed despite prior drug therapy. The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment whether the drug offers an added benefit over the appropriate comparator therapy in these patient groups.

7 Nov 2014

LSTM awarded research grants to develop Experimental Human Pneumococcal Carriage model

Respiratory specialists at Liverpool School Tropical Medicine have been awarded two substantial research grants to further develop and utilise their Experimental Human Pneumococcal Carriage (EHPC) model.

7 Nov 2014

Liposomes can help prevent bacterial toxins from killing human cells

Published in Nature Biotechnology, the study at the University of Liverpool showed that specially engineered lipid (fat) bodies, called liposomes, can be used to prevent bacterial toxins from killing human cells.

7 Nov 2014

Cardiome Pharma announces results from Phase 3 clinical study of BRINAVESS

Cardiome Pharma Corp. today announced results from a Phase 3 clinical study conducted with BRINAVESS (vernakalant intravenous, RSD 1235) in the Asia-Pacific (A-P) region.

7 Nov 2014

Neuronetrix selected to support upcoming ANAVEX 2-73 Phase 2a clinical trial

Neuronetrix has been selected by Anavex Life Sciences Corp. to support the upcoming Phase 2a clinical trial for ANAVEX 2-73, a symptomatic and potentially disease-modifying treatment for Alzheimer's disease. Neuronetrix will be utilizing their COGNISION System to measure and analyze cognitive biomarkers in study participants.

7 Nov 2014